Silence Therapeutics

Centre Point
103 New Oxford Street
London
WC 1A 1DD
UK

Tel: +44 (0) 20 7307 1620
Fax: +44 (0) 20 7307 1680
Email Us

Silence Therapeutics has developed novel, proprietary short interfering RNA (“siRNA”) molecules. These molecules provide a number of advantages over conventional siRNA molecules as they show increased stability against nuclease degradation. In addition, the Company has developed a proprietary systemic delivery system, AtuPLEX. This enables the delivery of siRNA molecules to targeted diseased tissues and cells in the body, whilst increasing their bioavailability and circulation times. Several of its proprietary AtuRNAi compounds are currently being developed clinically.

Further Information: http://www.silence-therapeutics.com

Related news from our archive

Silence Therapeutics to Merge with Intradigm Corp to Create RNAi Therapeutics Company
New company will have multiple RNAi discovery, development and delivery technologies and a broad portfolio of intellectual property.

Silence Therapeutics Receives Allowance from USPTO for its Core RNAi Patent
U.S. AtuRNAi patent allowance builds on European equivalent granted in 2007, expanding commercial protection.

Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
The study is designed to evaluate the effectiveness of a siRNA therapeutic product based on Silence’s AtuRNAi technology in diabetic macular oedema.

Silence Therapeutics Announces Successful Opposition of Glover Patent
Silence announces the successful opposition of a fundamental Alnylam European patent resulting in the patent being revoked in its entirety.